Portola Pharmaceuticals Inc (PTLA)

53.23
1.50 2.70
NASDAQ : Health Care
Prev Close 54.70
Open 54.69
Day Low/High 53.18 / 55.40
52 Wk Low/High 18.20 / 57.95
Volume 552.03K
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 57.66M
Market Cap 3.17B
EPS -4.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cramer: Don't Risk It All on a Small Biotech Unless You're Willing to Lose It All

Cramer: Don't Risk It All on a Small Biotech Unless You're Willing to Lose It All

Without at least one approved drug, I am tempted to say you should just take a pass.

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Jim Cramer says do your homework, be informed and don't let the wise guys trip you up with their warnings about 'single-stock risk.'

Short Interest In Portola Pharmaceuticals Drops 26.2%

Short Interest In Portola Pharmaceuticals Drops 26.2%

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 1,410,701 share decrease in total short interest for Portola Pharmaceuticals, Inc. , to 3,978,700, a decrease of 26.18% since 06/15/2017.

NovoCure, NextEra, O'Reilly: 'Mad Money' Lightning Round (7/7/17)

NovoCure, NextEra, O'Reilly: 'Mad Money' Lightning Round (7/7/17)

A look at Jim Cramer's thoughts on stocks of interest to "Mad Money" viewers.

What to Watch During the Week: Cramer's 'Mad Money' Recap (Friday 7/7/17)

What to Watch During the Week: Cramer's 'Mad Money' Recap (Friday 7/7/17)

Earnings and Fed speakers are on tap in the next few days.

These 3 Small Biotechs Have a Healthy Shot

These 3 Small Biotechs Have a Healthy Shot

Several firms hiked price targets on Portola into the $70s this week.

Give These 3 Small Biotechs a Shot

Give These 3 Small Biotechs a Shot

Several firms hiked price targets on Portola into the $70s this week.

Biotech Stocks Showing Signs Of Resurgence

MarketNewsUpdates.com News Commentary

Here Comes a Big Breakout For Alibaba

Here Comes a Big Breakout For Alibaba

What the charts say.

Portola Pharmaceuticals Presents Interim Phase 2a Safety And Efficacy Data For Cerdulatinib At The International Congress Of Malignant Lymphoma

Oral, Dual SYK/JAK Inhibitor Provides Opportunity for Differentiated Activity in B-cell and other Hematological Malignancies

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

4 Small-Cap Biotech Stars

4 Small-Cap Biotech Stars

I'm still enthusiastic about the sector, but it is critical to also be prudent.

4 Small-Cap Biotech Stars

4 Small-Cap Biotech Stars

I'm still enthusiastic about the sector, but it is critical to also be prudent.